Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database.
Expert Opin Drug Saf
; : 1-8, 2022 Oct 06.
Статья
в английский
| MEDLINE | ID: covidwho-2327415
ABSTRACT
BACKGROUND:
We study the adverse events (AEs) of bamlanivimab (BAM), bamlanivimab/etesevimab (BAM/ETE) to alert risk factors during coronavirus disease 2019 (COVID-19) treatment and provide references for drug safety. RESEARCH DESIGN ANDMETHODS:
Extract AEs from the COVID-19 Emergency Use Authorization (EUA) FDA Adverse Event Reporting System (FAERS) Public Dashboard. Disproportionality analysis was performed to discover the potential risks of BAM and BAM/ETE.RESULTS:
With COVID-19 drugs as the research background, the number of BAM/ETE signals is about half that of BAM, and 80% of signals overlap with BAM. Signals such as atrial fibrillation, tachycardia, and confusional state are present in BAM but not in BAM/ETE. With BAM and BAM/ETE as the research background, potential safety signals of BAM/ETE such as acute respiratory failure, hypersensitivity, and infusion-related reaction require long-term observation, especially acute respiratory failure which is not in the label.CONCLUSIONS:
The AEs report on this study confirm most of the label information of BAM and BAM/ETE. BAM/ETE is relatively safe, while the risk signals such as acute respiratory failure and infusion-related reaction require to be monitored.
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Тип исследования:
Экспериментальные исследования
/
Наблюдательное исследование
/
Прогностическое исследование
Язык:
английский
Журнал:
Expert Opin Drug Saf
Тематика журнала:
Фармакология
/
Лекарственная терапия
Год:
2022
Тип:
Статья
Аффилированная страна:
14740338.2023.2130888
Документы, близкие по теме
MEDLINE
...
LILACS
LIS